Barclays Forecasts Strong Price Appreciation for DaVita (NYSE:DVA) Stock

DaVita (NYSE:DVA) had its price target increased by research analysts at Barclays from $164.00 to $169.00 in a report issued on Tuesday,Benzinga reports. The brokerage presently has an “equal weight” rating on the stock. Barclays‘s price objective would indicate a potential upside of 7.68% from the stock’s previous close.

DaVita Stock Performance

NYSE:DVA opened at $156.95 on Tuesday. DaVita has a fifty-two week low of $118.56 and a fifty-two week high of $179.60. The firm’s 50 day moving average is $161.39 and its two-hundred day moving average is $157.80. The company has a market cap of $12.87 billion, a P/E ratio of 16.93, a P/E/G ratio of 0.84 and a beta of 0.94. The company has a quick ratio of 1.33, a current ratio of 1.37 and a debt-to-equity ratio of 15.78.

DaVita (NYSE:DVA) last issued its earnings results on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, beating analysts’ consensus estimates of $2.14 by $0.10. DaVita had a return on equity of 88.18% and a net margin of 6.53%. Analysts expect that DaVita will post 9.71 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the business. Transcendent Capital Group LLC acquired a new stake in shares of DaVita in the third quarter worth $25,000. SBI Securities Co. Ltd. acquired a new position in shares of DaVita during the fourth quarter worth about $41,000. Coppell Advisory Solutions LLC boosted its position in shares of DaVita by 50.0% in the fourth quarter. Coppell Advisory Solutions LLC now owns 300 shares of the company’s stock worth $45,000 after buying an additional 100 shares during the period. Blue Trust Inc. grew its stake in shares of DaVita by 56.4% in the third quarter. Blue Trust Inc. now owns 330 shares of the company’s stock valued at $54,000 after buying an additional 119 shares in the last quarter. Finally, Quarry LP acquired a new position in DaVita during the 3rd quarter worth approximately $60,000. Hedge funds and other institutional investors own 90.12% of the company’s stock.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.